Investigational drug GB1275 in combo with standard therapy for Advanced or Metastatic Cancers - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug, GB1275, is safe and effective for shrinking your cancer.
Advanced or Metastatic Cancer
Who Can Participate in the Study?
Adults with one of the following types of cancer:
-Esophageal cancer (cancer of the esophagus)
-Gastric adenocarcinoma (a type of stomach cancer)
-Gastroesophageal junction adenocarcinoma (a type of cancer that occurs where the esophagus meets the stomach)
-Pancreatic adenocarcinoma (a type of cancer of the pancreas)
-Triple-negative breast cancer (breast cancer that is missing certain receptors)
-Castrate-resistant prostate cancer (prostate cancer that doesn’t respond to homone-blocking therapies)
-Head and neck squamous cell carcinoma
-Urothelial carcinoma (a type of cancer found in the bladder or kidneys)
-Renal cell carcinoma (a type of kidney cancer)
-Hepatocellular carcinoma (a type of liver cancer)
What is Involved?
If you choose to join this study, you will:
-Take the study drug, GB1275, by mouth 2 to 3 times a day
-Give blood and urine samples
-Have regular CT or MRI scans
Some people will also:
-Get pembrolizumab into the vein (IV) once every 21 days; or
-Get nab-paclitaxel and gemcitabine into the vein (IV) on days 1, 8, and 15 of 28-day cycles